Bayer flags major Phase III results for stroke prevention drug asundexian
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
Muted movement reflects consolidation phase as investors await earnings triggers
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The national platform brought together healthcare professionals, patient advocates, and stakeholders
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
Subscribe To Our Newsletter & Stay Updated